HER2 Targeted ADCs: GI Cancers

CME

Emerging HER2-Targeted Antibody Drug Conjugates in Gastrointestinal Malignancies

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: April 09, 2024

Expiration: October 08, 2024

Zev A. Wainberg
Zev A. Wainberg, MD

Activity

Progress
1 2
Course Completed

Introduction

In this activity, Zev A. Wainberg, MD, reviews the recent developments in HER2 testing, appraises clinical trial results for anti-HER2 antibody‒drug conjugate (ADC) therapy, and discusses current strategies for managing the safety profile of ADCs for gastrointestinal (GI) cancers.

Please note that the slide thumbnails in this activity link to a PowerPoint slideset that also can be found here. The slideset also may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. A question will be asked twice: Once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your individual responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

For those providing patient care, how many patients with GI cancers do you provide care for in a typical month?

Your patient is receiving trastuzumab deruxtecan (T-DXd) as second-line therapy for advanced/recurrent HER2-positive GEJ adenocarcinoma and begins to develop what appears to be symptomatic grade 1 interstitial lung disease (ILD)/pneumonitis. What would be the most appropriate management strategy?